Records containing: Platinum-resistant Ovarian Cancer (PROC)

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-07
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
CLINICAL_TRIALS study record update · 2026-01-14
A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2025-07-20
Safety and Efficacy of Realgar-Indigo Naturalis Formula（RIF） Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study
CLINICAL_TRIALS study record update · 2024-11-25
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)
CLINICAL_TRIALS study record update · 2024-09-19
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in the Treatment of Patients with Recurrent Platinum-resistant Ovarian Cancer (Sunrise Trial): a Single-Arm, Exploratory Study
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2024-04-18
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors